Methods: Genetic analyses were performed by direct sequencing and multiplex ligation-7 dependent probe amplification; medical charts were analyzed retrospectively for 115 patients 8 with CLCNKB mutations. Functional analyses were performed in Xenopus laevis oocytes for 9 eight missense and two nonsense mutations.
10
Results: Sixty mutations, including 27 previously unreported mutations, were detected. The 11 phenotype was ante/neonatal Bartter Syndrome (polyhydramnios or diagnosis in the first 12 month of life) in 30% of cases, classic Bartter Syndrome (diagnosis during childhood, 13 hypercalciuria and/or polyuria) in 45% and Gitelman-like syndrome (fortuitous discovery of 14 hypokalemia with hypomagnesemia and/or hypocalciuria in childhood or adulthood) in 25%. 15 Nine of the 10 mutations expressed in vitro decreased or abolished chloride conductance. 16 Severe (large deletions, frameshift, nonsense, and essential splicing) and missense mutations 17 resulting in poor residual conductance were associated with younger age at diagnosis. 18 Electrolyte supplements and indomethacin were frequently used to induce catch-up growth 19 with few adverse effects. After a median follow-up of 8 years large deletions, and 10% splice-site mutations (Figure 1 ). Twenty-seven of these mutations 4 were previously unknown ( Figure 2A Clinical manifestations during follow-up and treatment were recorded for 77 patients (Table   14 3). Median follow-up was eight years and was similar in the three groups. in eight A/NBS and nine CBS patients are detailed in Table 3 . Proteinuria data were available 10 for 43 patients, nine of whom displayed glomerular proteinuria over 50 mg/dl.
11
Nineteen (10 female and 9 male patients) of the 77 patients (25%) presented CKD (Table 4) .
12
Ten patients presented stage 2 CKD: four A/NBS, four CBS, and two GLS patients. Two (Table 4 and Supplementary   19   Table 6 ). Patients with CKD were older than patients without CKD; they did not differ in 20 terms of birth weight, AINS treatment, urologic or renal abnormalities, or hypokalemia 21 severity (Table 6 ).
22
The last eGFR follow-up data for 30 patients with BS1, 34 patients with BS2, and 11 patients 23 with BS4a were compared with eGFR for the 77 patients with BS3. These groups had similar 24 age distribution, and eGFR decreased with age ( Supplementary Figure 1) . In BS1 and BS4 25 patients, eGFR decrease was more severe and there were higher proportions of patients with 1 CKD 3 to 5 than in BS2 and BS3 ( Supplementary Figures 1 and 2 Table 4 ). Three out of other five, classified as VOUS, were expressed in X. 15 laevis oocytes (p.Arg395Trp, p.Ala469Pro, and p.Gly345Ser) as were two previously 16 described mutations (p.Gly424Arg and p.Gly433Glu) detected as the only heterozygous 17 mutation in two patients. All these mutations significantly decreased chloride conductance. 18 The p.Ala510Thr, predicted in silico as pathogenic had a chloride conductance similar to that 19 of the wild-type channel. The molecular abnormality of patient heterozygous for this variant 20 thus remains unidentified. 21 In this large BS3 cohort, we confirmed the phenotypic variability, consisting of about 30%
A/NBS, 45% CBS, and 25% GLS ( Third, nineteen patients presented CKD, and seven of these patients also had proteinuria 5 ( Table 4) . Five patients underwent renal biopsy, which revealed diffuse glomerular and 6 tubulointerstitial lesions with enlarged glomeruli in four cases, suggesting compensatory 7 hypertrophy to nephron reduction (Table 4 and Supplementary progression including birth weight, age at diagnosis, long-term NSAID treatment, persistent 15 hypokalemia, and other renal abnormalities (Table 6 ). CKD has been described in other types 16 of BS 19, 22 . In our BS cohort, CKD was observed in all BS types but the proportion of patients 17 with preserved renal function (i.e., eGFR > 90 ml/min/1.73 m 2 ) was higher in patients with 18 BS types 2 and 3 and the proportion of patients with moderate to severe kidney disease (i.e., development is probably multifactorial, and its elucidation will require prospective studies. BS and no recurrence of FSGS, as previously described [41] [42] [43] . 25 16 In conclusion, BS3 syndrome, which is caused by CLCNKB mutations, is highly variable 1 phenotypically. We show, for the first time, that there is a correlation between severe 2 mutations and a significantly younger age at diagnosis, suggesting that milder defects of ClC-3 Kb function may account for some of this variability. We also confirmed the severe chloride 4 depletion previously observed in BS3 patients and report that 25% of cases suffer from CKD. 5 Long-term prospective follow-up of this cohort will identify other severity parameters 6 involved in this genotype/phenotype correlation and will allow us to evaluate whether early 7 diagnosis and treatment have an influence on the evolution to CKD. investigations were extended to both parents in 22 families and to the mother only in another 23 seven families. Twenty-three patients from this cohort have been described before 19, 23, 25 24 (Supplementary Tables 1 to 3 ). 
Bioinformatic analysis of mutations

22
The software used to interpret variants is described in the Supplementary Methods.
23
Functional expression in Xenopus laevis
24
Voltage clamp experiments were performed as previously described in Xenopus laevis 1 oocytes (25, 27 p.Gly345Ser (n=8), p.Gly433Glu (n=8), p.Ala510Thr (n=8) and p.Arg595Ter (n=3).
Figure 4: Correlation between plasma sodium and plasma chloride concentrations in patients 25 25 with BS type 1 and 2 (black symbol, grey area) and in patients with BS type 3 (white 1 symbols, orange area).
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